Skip to main content
SpringerLink
Log in

Resistant Hypertension: Recognition and Treatment

  • Chapter
  • First Online:
Hypertension and Cardiovascular Disease in Asia

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

Abstract

Hypertension is a very common chronic disease and suboptimal blood pressure (BP) control is the most attributable risk for death worldwide. The net and adjusted prevalence ratios of hypertension in the USA continue to increase, but due to increased awareness, there is slight improvement in the treatment and control of hypertension. Several large hypertension outcome trials, however, showed failure to achieve BP goals despite protocol defined treatment regimens, with 20–35% of the participants could not achieve BP control despite receiving more than three antihypertensive medications [1–4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69–75.

    Article  CAS  PubMed  Google Scholar 

  2. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–7.

    Article  CAS  PubMed  Google Scholar 

  3. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    Article  CAS  PubMed  Google Scholar 

  4. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.

    Article  CAS  PubMed  Google Scholar 

  5. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management from the American Heart Association. Hypertension. 2018;72:e53.

    Article  CAS  PubMed  Google Scholar 

  6. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13.

    CAS  PubMed  Google Scholar 

  7. Williams B, Manicai G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021.

    Article  PubMed  Google Scholar 

  8. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26.

    Article  PubMed  Google Scholar 

  9. Carey R, Sakhuja S, Calhoun DA, et al. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019;73(2):424–31.

    Article  CAS  PubMed  Google Scholar 

  10. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sison J, Divinagracia R, Nailes J. Asian management of hypertension: current status, home blood pressure and specific concerns in Philippines (a country report). J Clin Hypertens. 2020;22:504–7.

    Article  CAS  Google Scholar 

  12. Zabat GMA, Quiambao JL, Villaverde EC, et al. Clinical profile and management approach of diagnosed patients with resistant hypertension in a tertiary government hospital. Eur Heart J. 2013;34(supp 1):3226.

    Article  Google Scholar 

  13. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898.

    Article  PubMed  CAS  Google Scholar 

  14. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981–97.

    Article  Google Scholar 

  15. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlof B, et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian cardiac outcome trial (ASCOT): a risk score to identify those at high risk. J Hypertens. 2011;29:2004–13.

    Article  CAS  PubMed  Google Scholar 

  16. Tsujimoto T, Kajio H. Intensive blood pressure treatment for hypertension. Hypertension. 2018;73(2):415–23.

    Article  CAS  Google Scholar 

  17. Lewington S, MacMahon S. Blood pressure, cholesterol, and common causes of death: a review. Am J Hypertens. 1999;12:96–8.

    Article  Google Scholar 

  18. Freis ED. Veterans administration cooperative study group on hypertensive agents: effects of age on treatment results. Am J Med. 1991;90:20S–3S.

    Article  CAS  PubMed  Google Scholar 

  19. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594–9.

    Article  CAS  PubMed  Google Scholar 

  20. Lloyd-Jones DM, Evans JC, Larson MG, O’Donnell CJ, Levy D. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Hypertension. 1999;34:381–5.

    Article  CAS  PubMed  Google Scholar 

  21. Naseem R, Adam AM, Khan F, et al. Prevalence and characteristics of resistant hypertensive patients in an Asian population. Indian Heart J. 2017;69:442–6.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lotufo PA, Pereira AC, Vasconcellos PS, et al. Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults-Brazilian longitudinal study of adult health (ELSA-Brasil). J Clin Hypertens. 2015;17(1):74–80.

    Article  CAS  Google Scholar 

  23. Hannila-Handelberg T, Kontula K, Tikkanen I, et al. Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Med Genet. 2005;6:4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol. 2003;95:1297–300.

    Article  CAS  PubMed  Google Scholar 

  25. Moser M, Cushman W, Handler J. Resistant or difficult-to-treat hypertension. J Clin Hypertens. 2006;8:434–40.

    Article  Google Scholar 

  26. Kaplan NM. Resistant hypertension. J Hypertens. 2005;23:1441–4.

    Article  CAS  PubMed  Google Scholar 

  27. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol. 2007;88:683–92.

    Article  CAS  PubMed  Google Scholar 

  28. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens. 2008;10:130–9.

    Article  Google Scholar 

  29. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749–57.

    Article  PubMed  Google Scholar 

  30. Verdecchia P, Schillaci G, Borgioni C, et al. White coat hypertension and white coat effect. Similarities and differences. Am J Hypertens. 1995;8:790–8.

    Article  CAS  PubMed  Google Scholar 

  31. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712–8.

    Article  CAS  PubMed  Google Scholar 

  32. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093–100.

    Article  CAS  PubMed  Google Scholar 

  34. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension. 2002;40:464–9.

    Article  CAS  PubMed  Google Scholar 

  36. Bakris G, Hill M, Mancia G, et al. Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J Hum Hypertens. 2008;22:63–70.

    Article  CAS  PubMed  Google Scholar 

  37. Pickering TG. Measurement of blood pressure in and out of the office. J Clin Hypertens. 2005;7:123–9.

    Article  Google Scholar 

  38. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf. 1997;17:277–89.

    Article  CAS  PubMed  Google Scholar 

  39. Conlin PR, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension. 2000;36:461–5.

    Article  CAS  PubMed  Google Scholar 

  40. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959–63.

    Article  CAS  PubMed  Google Scholar 

  41. Aguilera MT, De la Sierra A, Coca A, Estruch R, Fernandez-Sola J, Urbano-Marquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension. 1999;33:653–7.

    Article  CAS  PubMed  Google Scholar 

  42. Wildman RP, Gu D, Muntner P, et al. Alcohol intake and hypertension subtypes in Chinese men. J Hypertens. 2005;23:737–43.

    Article  CAS  PubMed  Google Scholar 

  43. He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2004;3:CD004937.

    Google Scholar 

  44. Luft FC, Weinberger MH. Review of salt restriction and the response to antihypertensive drugs. Satellite symposium on calcium antagonists. Hypertension. 1988;11:229–32.

    Article  Google Scholar 

  45. Schafflhuber M, Volpi N, Dahlmann A, et al. Mobilization of osmotically inactive Na+ by growth and by dietary salt restriction in rats. Am J Physiol Renal Physiol. 2007;292:F1490–500.

    Article  CAS  PubMed  Google Scholar 

  46. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18:805–12.

    Article  CAS  PubMed  Google Scholar 

  47. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625–33.

    Article  PubMed  CAS  Google Scholar 

  48. Hall JE, Kuo JJ, Da Silva AA, de Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens. 2003;12:195–200.

    Article  CAS  PubMed  Google Scholar 

  49. Singer GM, Setaro JF. Secondary hypertension: obesity and the metabolic syndrome. J Clin Hypertens. 2008;10:567–74.

    Article  CAS  Google Scholar 

  50. Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. Cardiol Clin. 2010;28:639–54.

    Article  PubMed  Google Scholar 

  51. Kidney Disease Improving Global Outcomes (KDIGO) Blood Pressure Working Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):87.

    Google Scholar 

  52. Pisoni R, Ahmed MI, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep. 2009;11:407–13.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Long-term weight loss from lifestyle intervention benefits blood pressure? A systematic review. Hypertension. 2009;54:756–62.

    Article  CAS  PubMed  Google Scholar 

  54. Poobalan AS, Aucott LS, Smith WC, Avenell A, Jung R, Broom J. Long-term weight loss effects on all cause mortality in overweight/obese populations. Obes Rev. 2007;8:503–13.

    Article  CAS  PubMed  Google Scholar 

  55. He FJ, Marciniak M, Visagie E, et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension. 2009;54:482–8.

    Article  CAS  PubMed  Google Scholar 

  56. Grillo A, Salvi L, Coruzzi P, et al. Sodium intake and hypertension. Nutrients. 2019;11:1–16.

    Article  CAS  Google Scholar 

  57. Chobanian AV, Bakris GL, Black HR, et al. the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.

    Article  CAS  PubMed  Google Scholar 

  58. Appel LJ, Miller ER, Jee SH, et al. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation. 2000;102:852–7.

    Article  CAS  PubMed  Google Scholar 

  59. Moore TJ, Vollmer WM, Appel LJ, et al. Effect of dietary patterns on ambulatory blood pressure: results from the dietary approaches to stop hypertension (DASH) trial. Hypertension. 1999;34:472–7.

    Article  CAS  PubMed  Google Scholar 

  60. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the dietary approaches to stop hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999;159:285–93.

    Article  CAS  PubMed  Google Scholar 

  61. Kokkinos PF, Narayan P, Colleran JA, et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med. 1995;333:1462–7.

    Article  CAS  PubMed  Google Scholar 

  62. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493–503.

    Article  PubMed  Google Scholar 

  63. Czarina AM, Calhoun DA. Treatment of resistant hypertension. Minerva Cardioangiol. 2009;57:787–812.

    Google Scholar 

  64. Graves JW, Bloomfield RL, Buckalew VM Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci. 1989;298:361–5.

    Article  CAS  PubMed  Google Scholar 

  65. Taler SJ. Treatment of resistant hypertension. Curr Hypertens Rep. 2005;7:323–9.

    Article  CAS  PubMed  Google Scholar 

  66. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–53.

    Article  CAS  PubMed  Google Scholar 

  67. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

    Article  CAS  PubMed  Google Scholar 

  68. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–9.

    Article  CAS  PubMed  Google Scholar 

  69. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–8.

    Article  CAS  PubMed  Google Scholar 

  71. Khosla N, Chua DY, Elliott WJ, Bakris GL. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens. 2005;7:354–6.

    Article  Google Scholar 

  72. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–30.

    Article  CAS  PubMed  Google Scholar 

  73. Oparil S. The ASCOT blood pressure lowering trial. Curr Hypertens Rep. 2006;8:229–31.

    Article  PubMed  Google Scholar 

  74. Chapman JN, Kirby P, Caulfield MC, Poulter NR. Cardiovascular risk factors in a cohort of 30,000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Hum Hypertens. 2001;15(1):23–6.

    Article  Google Scholar 

  75. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol and doxazosin to determine the treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Gheorghiade M, Khan S, Blair JE, et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J. 2009;158:437–43.

    Article  CAS  PubMed  Google Scholar 

  77. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–8.

    Article  CAS  PubMed  Google Scholar 

  78. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovasc Drugs Ther. 2001;15:79–87.

    Article  CAS  PubMed  Google Scholar 

  79. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217–26.

    Article  CAS  PubMed  Google Scholar 

  80. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002;4:221–8.

    Article  PubMed  Google Scholar 

  81. Townsend RR, DiPette DJ, Goodman R, et al. Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther. 1990;48:665–75.

    Article  CAS  PubMed  Google Scholar 

  82. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6.

    Article  CAS  PubMed  Google Scholar 

  83. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.

    Article  PubMed  Google Scholar 

  84. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.

    Article  PubMed  Google Scholar 

  85. Bhatt DL, Kandzri DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393.

    Article  CAS  PubMed  Google Scholar 

  86. de Jager RL, de Beus E, Beeftink MM, et al. Impact of medical adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension. 2017;69:678.

    Article  PubMed  CAS  Google Scholar 

  87. Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive with or without denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957.

    Article  PubMed  Google Scholar 

  88. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765.

    Article  PubMed  Google Scholar 

  89. Spiering W, Williams B, der Heyden V, et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017;390:2655.

    Article  PubMed  Google Scholar 

  90. Wu CH, Wang Y, Murong M, et al. Antisense oligonucleotides targeting angiotensinogen: insights from animal studies. Biosci Rep. 2019;39(1):201.

    Article  Google Scholar 

  91. Ren L, Colafella KMM, Bovee DM, et al. Targeting angiotensinogen with RNA-based therapeutics. Curr Opin Nephrol Hypertens. 2020;29(2):180–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hypertension, Department of Medicine, University of the Philippines-Philippine General Hospital, Manila, Philippines

    Raymond V. Oliva

  2. American Heart Association Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago, Chicago, IL, USA

    George L. Bakris

Authors
  1. Raymond V. Oliva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George L. Bakris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raymond V. Oliva .

Editor information

Editors and Affiliations

  1. Apollo Hospitals, Apollo Institute for Blood Pressure Management, Hyderabad, India

    C. Venkata S. Ram

  2. Head, Division of Nephrology Department of Medicine, Yong Loo Lin Sch of Med Natl Univ of Sin, Singapore, Singapore

    Boon Wee Jimmy Teo

  3. Department of Cardiology, Hero DMC Heart Institute, Dayanand Medical College, Ludhiana, Punjab, India

    Gurpreet S. Wander

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Oliva, R.V., Bakris, G.L. (2022). Resistant Hypertension: Recognition and Treatment. In: Ram, C.V.S., Teo, B.W.J., Wander, G.S. (eds) Hypertension and Cardiovascular Disease in Asia. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-030-95734-6_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-95734-6_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-95733-9

  • Online ISBN: 978-3-030-95734-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation